DSRLF Stock Chart & Stats
$71.60
--
Market closed
$71.60
--
Day’s Range― - ―
52-Week Range$63.71 - $110.61
Previous CloseN/A
VolumeN/A
Average Volume (3M)71.00
Market Cap
$4.29B
Enterprise Value$4.62K
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$711.00M
Price to Earnings (P/E)27.7
Beta0.72
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.95%
Share Statistics
EPS (TTM)2.59
Shares Outstanding55,948,257
10 Day Avg. Volume3
30 Day Avg. Volume71
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)2.42
Price to Sales (P/S)3.21
P/FCF Ratio18.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$76.09Price Target Upside6.27% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)4.51
Revenue Forecast (FY)$1.40B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueDiaSorin’s business model ties instruments to repeat reagent and assay sales, producing predictable, utilization‑based revenue from installed systems. This durable revenue annuity supports stable cash flow, higher lifetime customer value, and more predictable planning over 2–6 months.
Strong Cash GenerationRobust TTM operating and free cash flow that exceed net income signal high earnings quality and cash conversion. This underpins durable financial flexibility to fund R&D, maintenance capex, dividends or debt reduction, and cushions the business through slower revenue periods.
High Operating MarginsSustained high gross and EBIT margins indicate structural pricing power and efficient operations in diagnostics. These margins provide room to absorb cyclical demand swings, sustain free cash flow, and reinvest in assay development and service capabilities over the medium term.
Bears Say
Softening Top-line GrowthA recent TTM revenue decline suggests slower demand or lower test volumes, which can impede expansion of the installed base and reduce future consumable consumption. Unless revenue growth stabilizes, recurring revenue cadence and long‑term growth potential may be constrained.
Net Margin Compression Vs Prior PeaksMaterial erosion of net margin from prior highs signals either pricing pressure, higher operating costs, or mix shifts. Persisting lower margins weaken return on capital, limit reinvestment and dividend capacity, and reduce buffer against revenue volatility.
Negative Free Cash Flow Growth TrendAlthough absolute free cash flow remains strong, recent negative FCF growth reduces momentum for further deleveraging, acquisitions, or accelerated R&D. A continued decline in FCF growth would constrain strategic flexibility and slow recovery toward prior performance levels.
DiaSorin S.p.A. News
DSRLF FAQ
What was DiaSorin S.p.A.’s price range in the past 12 months?
DiaSorin S.p.A. lowest stock price was $63.71 and its highest was $110.61 in the past 12 months.
What is DiaSorin S.p.A.’s market cap?
DiaSorin S.p.A.’s market cap is $4.29B.
When is DiaSorin S.p.A.’s upcoming earnings report date?
DiaSorin S.p.A.’s upcoming earnings report date is Nov 06, 2026 which is in 97 days.
How were DiaSorin S.p.A.’s earnings last quarter?
DiaSorin S.p.A. released its earnings results on Jul 31, 2026. The company reported $1.732 earnings per share for the quarter, beating the consensus estimate of $1.094 by $0.638.
Is DiaSorin S.p.A. overvalued?
According to Wall Street analysts DiaSorin S.p.A.’s price is currently Undervalued.
Does DiaSorin S.p.A. pay dividends?
DiaSorin S.p.A. pays a Annually dividend of $1.508 which represents an annual dividend yield of 1.95%. See more information on DiaSorin S.p.A. dividends here
What is DiaSorin S.p.A.’s EPS estimate?
DiaSorin S.p.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DiaSorin S.p.A. have?
DiaSorin S.p.A. has 55,948,257 shares outstanding.
What happened to DiaSorin S.p.A.’s price movement after its last earnings report?
DiaSorin S.p.A. reported an EPS of $1.732 in its last earnings report, beating expectations of $1.094. Following the earnings report the stock price went up 4.054%.
Which hedge fund is a major shareholder of DiaSorin S.p.A.?
Currently, no hedge funds are holding shares in DSRLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiaSorin S.p.A.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DSRLF Stock 12 Month Forecast
Average Price Target
$76.09
▲(6.27% Upside)
Amplifon S.p.A.
―
El.En. S.p.A.
―
Fidia Spa
―
Recordati Industria Chimica e Farmaceutica SPA
―
Safilo Group SpA
―
Ownership Overview
8.49% Insiders
2.83% Mutual Funds
― Other Institutional Investors
86.45% Public Companies and
Individual Investors